January/February 2015

While there is increased awareness and activity in the area of patient engagement, efforts to advance the concept are fragmented and disjointed.

The prevalence and proportion of spend on high-cost generic drugs is examined.

Description of strategies that employers can consider to better manage their PBM relationship to optimize their pharmacy benefit costs.

Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.

Mechanisms of drug-induced liver injury in children, case reports of atomoxetine-induced liver injury in children, and nonstimulant options for attention-deficit/hyperactivity disorder.

As new care delivery models evolve to focus on value, accountability, and team-based care, new measure development opportunities exist to address care gaps and to support team-based care delivery systems and care transitions.

This study provides real-world evidence of a teriparatide (TPTD) patient’s characteristics, sequence of care, and healthcare resource utilization, and compares TPTD patients with non-TPTD patients.

A retrospective cohort analysis was conducted to compare disease-specific healthcare resource utilization and the costs of collagenase clostridium histolyticum and fasciectomy among adult Dupuytren’s contracture patients.

This CE activity will cover the clinical symptoms and pathophysiology of narcolepsy while addressing the economic and social burdens of this disease. A treatment monitoring plan and multidisciplinary strategies for selection of appropriate and cost-effective therapy will also be discussed.

Narrowing consumer choice is the big issue for 2015.